Abstract

MDC are developing more translational models that better reflect the patient population, to address the poor correlation between clinical and animal data. Biomarker analysis is key in demonstrating a models reflection of patient disease.
Neuroinflammation is a complex integration of the responses of all cells present within the CNS, including the neurons, macroglia, microglia and the infiltrating leukocytes. Neuron-microglia co-cultures treated with pro-inflammatory agents are a useful tool to study neuroinflammation in vitro.
How do we know these in vitro tools represent patient disease?
Here we describe a range of emerging biomarker technologies used to characterise drug and disease such as pre-clinical animal and mass spec imaging, along with digital spatial profiling platforms to demonstrate back translation from patient to the bench.